Renaissance Technologies’s Mineralys Therapeutics MLYS Stock Holding History

Renaissance Technologies’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.2M	Sell	378,300 -4,500	-1%	-$123K	0.01%	1047
2026 Q1	$10.4M	Buy	382,800 +60,700	+19%	+$1.78M	0.02%	950
2025 Q4	$11.7M	Buy	322,100 +274,700	+580%	+$11M	0.02%	841
2025 Q3	$1.8M	Sell	47,400 -129,526	-73%	-$2.8M	﹤0.01%	2142
2025 Q2	$2.39M	Sell	176,926 -374	-0.2%	-$5.42K	﹤0.01%	2001
2025 Q1	$2.82M	Buy	177,300 +57,800	+48%	+$665K	﹤0.01%	1781
2024 Q4	$1.47M	Buy	119,500 +15,700	+15%	+$205K	﹤0.01%	2258
2024 Q3	$1.26M	Buy	103,800 +42,000	+68%	+$508K	﹤0.01%	2308
2024 Q2	$723K	Buy	61,800 +30,100	+95%	+$379K	﹤0.01%	2504
2024 Q1	$409K	Buy	31,700 +6,200	+24%	+$76.6K	﹤0.01%	2951
2023 Q4	$219K	Sell	25,500 -70,190	-73%	-$551K	﹤0.01%	3105
2023 Q3	$910K	Buy	+95,690	New	+$1.25M	﹤0.01%	2375

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Renaissance Technologies's MLYS Position: Q2 2026 in Review

Renaissance Technologies reduced its Mineralys Therapeutics (MLYS) stake by 1.2% in Q2 2026, selling an estimated $123K and leaving 378,300 shares worth $10.2M. The position accounts for 0.01% of the portfolio, ranked #1047.

Renaissance Technologies first reported a position in MLYS in Q3 2023 and has held it in 12 quarters since. The position peaked at $11.7M in Q4 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

Renaissance Technologies held 378,300 shares of Mineralys Therapeutics worth $10.2M as of Q2 2026.
Renaissance Technologies sold 4,500 Mineralys Therapeutics shares in Q2 2026, an estimated $123K.
Mineralys Therapeutics made up 0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1047 holding.
Renaissance Technologies first reported a position in Mineralys Therapeutics in Q3 2023 and has held it in 12 quarters since.
Renaissance Technologies's Mineralys Therapeutics position peaked at $11.7M in Q4 2025.
224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.